newsfilter
← Latest News
Business Wire·

AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

– Total Q3 2021 Revenue of $15.2 Million Includes FOTIVDA® (tivozanib) U.S. Net Product Revenue of $14.3 Million –– Enrollment Open for Pivotal Phase 3 TiNivo-2 Clinical Trial of FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) –